ALXO
Overvalued by 99.3% based on the discounted cash flow analysis.
Market cap | $843.50 Million |
---|---|
Enterprise Value | - |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $0.0 |
Beta | 0.0 |
Outstanding Shares | 50,000,000 |
Avg 30 Day Volume | 654,897 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 0.0 |
---|---|
PEG | - |
Price to Sales | - |
Price to Book Ratio | - |
Enterprise Value to Revenue | - |
Enterprise Value to EBIT | - |
Enterprise Value to Net Income | - |
Total Debt to Enterprise | - |
Debt to Equity | - |
No data
No data
ALX Oncology Holdings Inc. operates as a clinical stage immuno-oncology company. The Company focuses on helping patients fight cancer by developing therapies that bridge the innate and adaptive immune system. ALX Oncology Holdings serves patients in the State of California.